Bevacizumab News and Research

RSS

Bevacizumab is a recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine. Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.

Key kinase involved in cell division linked to abnormal blood vessel growth in genetic disorder

Inhibition of CDK6 may prevent arteriovenous malformations in hereditary hemorrhagic telangiectasia by regulating endothelial cell cycle progression.

8 Nov 2024

Targeted therapy and immunotherapy improve outcomes in rare thyroid cancer

Researchers from The University of Texas MD Anderson Cancer Center demonstrated that anti-PD-L1 immunotherapy in combination with mutation-directed targeted therapy extended overall survival (OS) in patients with anaplastic thyroid carcinoma (ATC). Findings from the Phase II single center study published today in JAMA Oncology.

24 Oct 2024

High-dose vitamin D3 cannot be recommended as treatment for metastatic colon cancer

A double-blind randomized phase 3 clinical trial led by Dana-Farber Cancer Institute researchers and conducted across several hundred cancer centers in the U.S. tested the addition of high-dose vitamin D3 to standard treatment for patients with untreated metastatic colorectal cancer.

16 Sep 2024

Gut bacteria may influence immunotherapy success in mesothelioma patients

A cancer study has found that certain gut bacteria may influence whether or not a patient's immune system is successful in fighting mesothelioma, an aggressive form of cancer.

5 Sep 2024

Review explores potential for improved use of anti-angiogenic agents in cancer therapy

Most tumors release various signaling molecules to support their incessant growth, invasion, and metastasis.

9 Aug 2024

Immunotherapy-chemotherapy combo boosts survival for patients with metastatic colorectal cancer

A study led by UCLA Health Jonsson Comprehensive Cancer Center researchers found that using a combination of experimental immunotherapy drugs with chemotherapy significantly improves progression-free survival and overall survival for patients with metastatic colorectal cancer who have previously undergone standard chemotherapy treatment when compared to those who received the targeted therapy regorafenib alone.

24 May 2024

Leveraging cancer therapies to combat tuberculosis

What could cancer teach us about tuberculosis? That's a question Meenal Datta has been chasing since she was a graduate student.

25 Mar 2024

Innovative CAR T cell therapy targets two proteins to combat aggressive brain tumor growth

Breakthrough in Brain Cancer Treatment: Dual-Target CAR T Cell Therapy Shows Promise in Early Clinical Trial.

15 Mar 2024

Study paves the way for improving personalized treatment of patients with glioblastoma

A study led by the ITACA Institute of the Universitat Politècnica de València, with the participation of the Institut Català d'Oncologia (ICO), the Institut Investigació Germans Trias I Pujol (IGTP) and the Hospital Clinic de Barcelona, opens up a novel approach for improving personalized treatments for patients with glioblastoma, one of the most aggressive types of cancer in existence today.

31 Jan 2024

Children with neuroblastomas may benefit from new drug cocktail

Children who develop neuroblastomas, a rare form of cancer which develops in nerve cells, may benefit from receiving certain anti-tumor drugs as well as chemotherapy, a new trial has found.

9 Jan 2024

Tumor debulking does not impact quality of life in metastatic colorectal cancer, study finds

New research in the October 2023 issue of JNCCN-;Journal of the National Comprehensive Cancer Network finds that intensive local-regional treatment to remove as much tumor as possible (known as "debulking"), in addition to standard systemic therapy, does not impact overall quality of life significantly for people with metastatic colorectal cancer.

13 Oct 2023

ACT and personalized cancer vaccine combo shows efficacy in ovarian cancer patients

A Ludwig Cancer Research study has shown that combining adoptive T cell therapy (ACT) with an innovative, personalized cancer vaccine under development at the Lausanne Branch of the Ludwig Institute for Cancer Research can benefit patients with late-stage, drug-resistant ovarian cancer.

21 Sep 2023

The role of diet in the management of retinal vein occlusion

Researchers investigate the potential impact of dietary habits on retinal vein occlusion.

27 Jul 2023

The potential prognostic role of AhRR and PPP1R3C expression in serous ovarian cancer

Study evaluated genes with copy number alterations to identify biomarkers for ovarian cancer prognosis.

18 Jul 2023

Mays Cancer Center conducts clinical trial combining two drugs in patients with recurrent, high-grade glioblastoma

The Mays Cancer Center at The University of Texas Health Science Center at San Antonio recently conducted a clinical trial combining two drugs in patients with recurrent, high-grade glioblastoma (GBM).

24 May 2023

Study finds socio-economic inequalities in access to novel therapies for many NSCLC patients

Novel anti-cancer therapies were not accessible to more than half of the patients in England who were diagnosed with non-small cell lung cancer, according to a new study published in the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer.

19 May 2023

Correcting abnormalities in solid tumor's blood vessels can improve efficacy of CAR-T cell therapy

A type of immune therapy called chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of multiple types of blood cancers but has shown limited efficacy against glioblastoma-;the deadliest type of primary brain cancer-;and other solid tumors.

14 Mar 2023

Pembrolizumab offers major added survival benefit for patients with advanced cervical cancer

Pembrolizumab has recently been approved in combination with chemotherapy for the treatment of women with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1. Chemotherapy with or without bevacizumab is possible.

25 Jan 2023

Plasma GH is a biomarker candidate for predicting outcomes in advanced HCC patients treated with Atezo/Bev

A new research paper was published in Oncotarget's Volume 13 on December 6, 2022, entitled, "Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients."

22 Dec 2022

Study compares the performance of two most popular AMD drugs

A pilot, "look-back" study of information about 106 patients with "wet" age-related macular degeneration (AMD) treated at the Wilmer Eye Institute at Johns Hopkins Medicine has revealed that nearly half of patients treated with aflibercept could safely stop eye injection therapy after one year without further vision loss.

30 Nov 2022